Yarrow Bioscience, Inc. is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company is developing YB-101, an anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' Disease (GD) and Thyroid Eye Disease (TED), offering a single targeted treatment to address both diseases. By blocking TSHR, the common target of autoantibodies in both the thyroid and the eye, YB-101 has the potential to rapidly arrest the disease process and provide improved efficacy and safety versus the standard of care and other mechanisms in development. YB-101 is designed for convenient subcutaneous administration, with the potential for infrequent dosing and future autoinjector presentations. The Company has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED.
Back to dashboard
Company Information
About this company
Key people
Bill Lundberg
Chairman of the Board
William White
Director
Rebecca Velez Frey
Chief Executive Officer, Director
Tyler Zeronda
Chief Financial Officer
Rachael Alford
Chief Operating Officer
Lori Payton
Chief Development Officer
Steven W. Ryder
Chief Medical Officer
Mona Ashiya
Director
Steven L. Hoerter
Director
Peter B. Silverman
Director
Click to see more
Key facts
- Shares in issue2.80m
- EPICYARW
- ISINUS92941V4077
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market capGBX 0.00
- Employees10
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.